---
type: research
topic: "Real Chemistry/Swoop Impact on Solstice Health Strategy"
date: 2025-12-28
assessment: ANSWERED
iterations: 1
vault_sources: 8
web_sources: 6
---

# Solstice Is Building the MLR Layer That New Mountain's $30B Health-Tech Empire Lacks—Acquisition or Competition Are the Only Outcomes

Real Chemistry's success ($665M revenue, $3.1B valuation) validates the pharma commercialization market Solstice now targets. But the Swoop spinoff (September 2024) and Matt Holt's Thoreau deal ($30B health-tech consolidation) reveal a critical gap: New Mountain owns content creation, omnichannel activation, and data connectivity—but not the MLR compliance technology that gates all pharma content. Solstice's Pre-MLR tool sits exactly in that white space. The strategic question isn't whether Solstice competes with Real Chemistry—it's whether New Mountain acquires Solstice to complete the stack, or Solstice becomes a standalone challenger with better margins.

---

## Solstice's Pivot Directly Targets Real Chemistry's Market

Solstice abandoned community provider records retrieval in March 2024 after concluding there was insufficient willingness-to-pay for 6-figure contracts [[copy-of-running-meeting-notes---virtue-_-solstice-74b9744d.md]]. By May 2024, the company pivoted to life sciences marketing with explicit positioning:

> "You can think of us as Real Chemistry but faster, more efficient, and with even better margins." [[2025-12-21_solstice-fundraise-planning-58766694.md]]

**Current Solstice product:**
- **Pre-MLR Tool** — Regulatory compliance checking before Medical Legal Review
- **Auto-annotations** — AI-powered fact-checking and reference linking
- **Content Creation** — Generating promotional messages from claims

**Current traction (December 2025):** ~$300-420k ARR signed (Phathom $120k, Ipsen $180k, Sanofi $100k, Incyte $19k), with $1M+ in procurement (Takeda $500k, Nuvation $300k, AstraZeneca $200k+) [[2025-12-21_solstice-fundraise-planning-58766694.md]].

---

## Real Chemistry / Swoop: What New Mountain Built

New Mountain acquired W2O Group (now Real Chemistry) in June 2019 for ~$625M [[wb-hcit-life-sciences-pharmacy-it-and-services-landscape-su-92e04bd9]] and has executed 10+ acquisitions since:

| Year | Acquisition | Capability Added |
|------|-------------|------------------|
| 2021 | Swoop + IPM.ai | Data/analytics, audience targeting |
| 2022 | ConversationHealth | Conversational AI agents |
| 2023 | TI Health | HCP engagement (folded into Swoop) |
| 2024 | Avant Healthcare | Medical communications |
| 2025 | Greater Than One | Digital media agency |
| 2025 | Spring & Bond | Precision marketing, omnichannel |

**September 2024:** New Mountain spun Swoop off as standalone company while maintaining ownership of both. Rationale: separate high-growth tech asset from services business for different exit paths. Swoop now partners with Real Chemistry competitors (Ogilvy Health, Klick Health, Evoke)—"arms dealer" strategy enabled by independence [[2025-12-28-real-chemistry-solstice-impact]].

**April 2025:** $3.1B single-asset continuation vehicle for Real Chemistry—proves biopharma commercialization is a billion-dollar outcome market [[2025-12-28-real-chemistry-solstice-impact]].

---

## The Gap: No PE Platform Owns MLR Technology

Despite billions deployed in pharma marketing consolidation, **no major PE-backed platform has acquired a specialized MLR technology company since Veeva's Zinc Ahead deal ($130M, 2015)** [[Solstice RM Comparison]].

Real Chemistry's stack:
- **Content creation** — Agencies create materials
- **Omnichannel activation** — Swoop targets and delivers
- **Data/analytics** — 300M+ patient records

What they DON'T own:
- **MLR review workflow** — Sends content to Veeva Vault PromoMats
- **Pre-submission compliance** — No automated checking before MLR

Current MLR pain points:
- Average review cycle: **50-60 days** at mid/large pharma
- Emails can take **3+ months** from idea to deployment
- Agencies charge **$50k for a 10-page deck**
- 27 combined hours to fact-check one detail aid (~$20k) [[2025-12-21_solstice-fundraise-planning-58766694.md]]

**Solstice's Pre-MLR tool fills exactly this gap.** It reduces the 3-month cycle to minutes by checking compliance before content enters the formal MLR queue.

---

## Matt Holt's Thoreau: The $30B Consolidation Play

In December 2025, Matt Holt departed New Mountain to form Thoreau, targeting five New Mountain health-tech assets under one umbrella [[Holt exits New Mountain to create $30 billion health-tech venture.md]]:

| Company | Focus |
|---------|-------|
| Datavant | Healthcare data connectivity, 2,000+ hospitals |
| Swoop | Pharma omnichannel marketing tech |
| Machinify | Payment integrity AI |
| Smarter Technologies | Revenue cycle AI |
| Office Ally | Clearinghouse/billing |

Backed by ICG Strategic Equity with Middle East capital. New Mountain retains ~$2B stake while booking ~$14B for LPs.

**Key quote from New Mountain investor letter:**
> "We believe there is strong logic to putting all five companies together under one holding company umbrella, to enable the creation of a flexible and strong new competitor in the AI-enabled health tech space."

**Notable absence:** No MLR/compliance technology in the Thoreau stack.

---

## Strategic Implications for Solstice

### Scenario 1: Acquisition Target (Most Likely)

New Mountain/Thoreau could acquire Solstice to complete the pharma commercialization stack:
- **Real Chemistry/Swoop** — Creates and delivers content
- **Solstice** — Ensures content is compliant before MLR
- **Integration value** — Tighter cycle from creation to approval

**Valuation context:** Real Chemistry at $3.1B with $665M revenue = ~4.7x revenue. Solstice at $10M ARR goal would imply ~$47M at similar multiple, though premium for technology vs. services.

### Scenario 2: Standalone Challenger

Solstice builds independently with better unit economics:
- Real Chemistry margins: Agency model (high labor cost)
- Solstice margins: Software model (AI-powered, low marginal cost)

**Risk:** Real Chemistry is well-capitalized and on aggressive M&A spree. They could build/buy competing MLR capability.

### Scenario 3: Partnership

Solstice becomes MLR technology partner to Real Chemistry (or its competitors):
- Similar to Swoop's "arms dealer" strategy post-spinoff
- White-labels Pre-MLR tool to agencies who lack compliance tech

---

## Recommendations

1. **Track Thoreau deal close** — If Holt consolidates the five assets, watch for MLR technology acquisition to complete stack
2. **Monitor Real Chemistry M&A** — Greater Than One and Spring & Bond in 2025 show continued appetite; MLR is logical next gap
3. **Validate Solstice differentiation** — Can Pre-MLR tool integrate with Veeva Vault PromoMats? That's the enterprise unlock
4. **EVERSANA watch** — Their April 2025 MLR launch (90% automation claim) is direct competition; need head-to-head benchmark

**Bull case:** New Mountain/Thoreau acquires Solstice at premium to fill MLR gap; integration with Real Chemistry creates end-to-end pharma content platform

**Bear case:** Real Chemistry builds MLR capability internally or acquires competitor (EVERSANA has first-mover in PE-backed MLR); Solstice stuck competing against well-capitalized incumbent

---

## Research Process
- Iterations: 1
- Vault patterns: `Solstice.*2024|2025`, `Real.?Chemistry|Swoop`, `New.?Mountain|Matt.?Holt`, `MLR|medical.?legal.?regulatory`
- Web queries: 4 (`Swoop New Mountain Real Chemistry acquisition 2024`, `Real Chemistry pharma marketing MLR platform`)
- Web sources fetched: 6
- Total cost: $0

## Sources

### Vault
- [[2025-12-21_solstice-fundraise-planning-58766694.md]] — December 2025 Solstice fundraise planning with current traction
- [[2025-12-28-real-chemistry-solstice-impact]] — Prior analysis of Real Chemistry impact
- [[Solstice RM Comparison]] — MLR landscape and competitive positioning
- [[copy-of-running-meeting-notes---virtue-_-solstice-74b9744d.md]] — Meeting notes documenting pivot (March 2024)
- [[copy-of-running-meeting-notes---virtue-solstice-59d233a9.md]] — Meeting notes (May-August 2024)
- [[Claude-Understanding real chemistry and life sciences commercialization]] — Real Chemistry overview
- [[Holt exits New Mountain to create $30 billion health-tech venture.md]] — Thoreau deal details
- [[wb-hcit-life-sciences-pharmacy-it-and-services-landscape-su-92e04bd9]] — William Blair landscape report

### Web
- [New Mountain Capital Establishes Swoop as Independent Company](https://www.businesswire.com/news/home/20240904145950/en/) — September 2024 spinoff announcement
- [Swoop spins off from Real Chemistry](https://www.prweek.com/article/1887438/swoop-spins-off-real-chemistry) — PR Week coverage
- [Real Chemistry strikes partnership with Corval](https://www.mmm-online.com/home/channel/real-chemistry-partnership-corval-pharma-commercialization/) — Commercialization platform partnership
- [Real Chemistry launches HealthGEO tool](https://www.mmm-online.com/news/real-chemistry-launches-new-healthgeo-tool/) — AI content optimization
- [How pharma marketers are using AI](https://www.fiercepharma.com/marketing/how-pharma-marketers-are-using-ai-content-creation-efficiency-boosts-while-navigating) — Industry AI adoption
- [Swoop nabs MyHealthTeam](https://www.mmm-online.com/news/swoop-nabs-myhealthteam-poised-for-more-deals/) — December 2024 acquisition
